Literature DB >> 17389782

Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.

Dimitrios S Goumenos1, Konstantinos P Katopodis, Ploumis Passadakis, Eleftheria Vardaki, Vasilios Liakopoulos, Eugenios Dafnis, Ioannis Stefanidis, Vasilios Vargemezis, Jannis G Vlachojannis, Kostas C Siamopoulos.   

Abstract

BACKGROUND/AIM: Idiopathic membranous nephropathy, the most common cause of nephrotic syndrome in adults, has been traditionally treated with corticosteroids and cytotoxic drugs. Ciclosporin A (CsA) is used in resistant cases, but also as a first-line treatment, due to the serious side effects of cytotoxic drugs. In this study, the remission rates of nephrotic syndrome and the incidence of side effects of corticosteroids and low CsA doses are compared with those after treatment with cytotoxic drugs.
METHODS: Seventy-seven nephrotic patients with well-preserved renal function who were treated with methylprednisolone and CsA (n = 46) or cytotoxic drugs (n = 31) were studied. The effects of treatments were estimated on the basis of remission rates of nephrotic syndrome and preservation of the renal function.
RESULTS: Remission (complete or partial) of nephrotic syndrome was observed in 85% of the patients treated with CsA and in 55% of the patients treated with cytotoxic drugs (p < 0.01). Deterioration of the renal function, more common in patients with multiple relapses and interstitial fibrosis, was observed in 26 and 23% of the patients, respectively (p = NS). Serious side effects and discontinuation of treatment were more frequent in patients treated with cytotoxic drugs (10 vs. 4%).
CONCLUSION: The combination of corticosteroids with CsA represents a better regimen for patients having idiopathic membranous nephropathy, since it is associated with higher remission rates of nephrotic syndrome and less severe side effects than corticosteroids and cytotoxic drugs. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389782     DOI: 10.1159/000101367

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

Review 1.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

2.  Lupus-like membranous nephropathy: Is it lupus or not?

Authors:  Ramin Sam; Amit Joshi; Sam James; Kuang-Yu Jen; Firouz Amani; Peter Hart; Melvin M Schwartz
Journal:  Clin Exp Nephrol       Date:  2014-07-04       Impact factor: 2.801

Review 3.  Controversies in the treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  Nat Rev Nephrol       Date:  2009-07-07       Impact factor: 28.314

Review 4.  Treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

5.  Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study.

Authors:  Jia Wang; Qionghong Xie; Zhuxing Sun; Ningxin Xu; Yan Li; Liang Wang; Shaojun Liu; Jun Xue; Chuan-Ming Hao
Journal:  BMC Nephrol       Date:  2017-07-10       Impact factor: 2.388

6.  Baicalin protects against renal interstitial fibrosis in mice by inhibiting the TGF-β/Smad signalling pathway.

Authors:  Hui Wang; Qingtao Jiang; Lizhu Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

7.  A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.

Authors:  Jorge Rojas-Rivera; Gema Fernández-Juárez; Alberto Ortiz; Julia Hofstra; Loreto Gesualdo; Vladimir Tesar; Jack Wetzels; Alfons Segarra; Jesus Egido; Manuel Praga
Journal:  Clin Kidney J       Date:  2015-09-24

8.  The impact of coexisting diabetes mellitus on clinical outcomes in patients with idiopathic membranous nephropathy: a retrospective observational study.

Authors:  Zhiyong Xie; Zhilian Li; Wei Dong; Yuanhan Chen; Ruizhao Li; Yanhua Wu; Huaban Liang; Zhiming Ye; Shuangxin Liu; Wei Shi; Xinling Liang
Journal:  BMC Nephrol       Date:  2020-06-12       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.